NCT02154308View on ClinicalTrials.gov

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

787

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

August 31, 2013

Conditions
Healthy
Interventions
BIOLOGICAL

IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL

IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection

Trial Locations (1)

Unknown

Incheon St. Mary's Hospital, The Catholic University of Korea etc, Total 10 hospitals., Seoul Etc

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY

NCT02154308 - Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Adults | Biotech Hunter | Biotech Hunter